NCT06673056 - A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 1, 2028

Conditions

Ataxia-TelangiectasiaAtaxia-Telangiectasia (A-T)

Interventions

DRUG

N-Acetyl-L-Leucine

N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

OTHER

Placebo

Matching Placebo Sachet

Trial Locations (11)

University of Bern, Bern

Hospital Universitario La Paz, Madrid

University of Giessen, Giessen

University of Cologne, Cologne

The University of Texas Health (UT Health), Houston

University of California Los Angeles, Los Angeles

Massachusetts General Hospital, Boston

Comenius University Bratislava, Bratislava

University Hospital L. Pasteur, Košice

Royal Papworth Hospital, Cambridge

University of Nottingham, Nottingham